Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

GH effect on enzyme activ… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

GH effect on enzyme activity of 11betaHSD in abdominal obesity is dependent on treatment duration.

Artikel i vetenskaplig tidskrift
Författare Helga A Sigurjónsdóttir
Josef Koranyi
Magnus Axelson
Bengt-Åke Bengtsson
Gudmundur Johannsson
Publicerad i European journal of endocrinology / European Federation of Endocrine Societies
Volym 154
Nummer/häfte 1
Sidor 69-74
ISSN 0804-4643
Publiceringsår 2006
Publicerad vid Institutionen för medicin, avdelningen för invärtesmedicin
Sidor 69-74
Språk en
Länkar dx.doi.org/10.1530/eje.1.02061
Ämnesord 11-beta-Hydroxysteroid Dehydrogenase Type 1, blood, 11-beta-Hydroxysteroid Dehydrogenase Type 2, blood, 11-beta-Hydroxysteroid Dehydrogenases, blood, drug effects, Abdominal Fat, drug effects, Human Growth Hormone, administration & dosage, therapeutic use, Humans, Hydrocortisone, blood, Insulin Resistance, physiology, Male, Middle Aged, Obesity, drug therapy, enzymology, Time Factors
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

OBJECTIVE: In the past years the interaction of GH and 11beta hydroxysteroid dehydrogenase (11betaHSD) in the pathogenesis of central obesity has been suggested. DESIGN: We studied the effects of 9 months of GH treatment on 11betaHSD activity and its relationship with body composition and insulin sensitivity in 30 men with abdominal obesity, aged 48-66 years, in a randomised, double-blind, placebo-controlled trial. METHODS: Urinary steroid profile was used to estimate 11betaHSD type 1 and 2 (11betaHSD1 and 11betaHSD2) activities. Abdominal s.c. and visceral adipose tissues were measured using computed tomography. Glucose disposal rate (GDR) obtained during a euglycaemic-hyperinsulinaemic glucose clamp was used to assess insulin sensitivity. RESULTS: In the GH-treated group the 11betaHSD1 activity decreased transiently after 6 weeks (P < 0.01) whereas 11betaHSD2 increased after 9 months of treatment (P < 0.05). Between 6 weeks and 9 months, GDR increased and visceral fat mass decreased. Changes in 11betaHSD1 correlated with changes in visceral fat mass between baseline and 6 weeks. There were no significant correlations between 11betaHSD1 and 11betaHSD 2 and changes in GDR. DISCUSSION: The study demonstrates that short- and long-term GH treatment has different effects on 11betaHSD1 and 11betaHSD2 activity. Moreover, the data do not support that long-term metabolic effects of GH are mediated through its action on 11betaHSD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?